Bitcoin's price momentum toward $90,000 has weakened, stalling below $87,722 amid a sharp 90% decline in weekly U.S. spot ETF inflows, falling from $2.39 billion to $241.1 million. Analysts from Bitfinex highlight that ETF investors have just regained their average entry price after 233 days underwater, which may explain the current buying hesitation. The outlook remains cautiously bullish with Bitcoin expected to trade between $84,000 and $87,722, but sustained trading below $81,300 combined with ETF outflows could threaten the recovery and push prices toward $77,000. Upcoming U.S. inflation data and Federal Reserve decisions will also influence Bitcoin's trajectory in the near term.
Bitcoin's recent price action is noted here with Pluang's market snapshot as of Oct 07, 2026 00:03 WIB: Among 50 major cryptocurrencies, 24 rose and 25 fell today. Key movers include ONE at Rp41 with a 2.20% decline and 82% buy orders, COMP at Rp439.415 down 2.15% with 70% buy orders, and SAND at Rp1.171 down 2.07% with 63% sell orders.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
